UCB touts positive results in Crohn's drug trials

Belgian biopharma UCB said final trials of Cimzia, a potential blockbuster drug for Crohn's disease, yielded "significant positive" results. The company plans to apply within nine months to start selling the drug in Europe and the US. UCB said both phase III trials assessing the safety and efficacy of Cimzia had achieved "statistical significance" compared to the control groups in the trials and showed that the drug is "highly effective" at reducing Crohn's symptoms. UCB is also working to get approval to market Cimzia to treat rheumatoid arthritis.

- read this press release for more

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.